Shots: Seattle Genetics to receive $600M up front, $1B as equity investment, 5M shares of Seattle Genetics common stock at a price of $200/ share, ~$2.6B as milestones including $850M […]readmore
Tags : Seattle Genetics
Shots: HER2CLIMB study involves assessing of Tukysa (tucatinib) + trastuzumab + capecitabine vs trastuzumab + capecitabine alone in 612 patients in a ratio (2:1) with LA unresectable/m-HER2+ BC prior treated […]readmore
The US FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 48 new products so far in 2019 However, there is […]readmore
Shots: The BT designation is based on P-Ib/II EV-103 study assessing Padcev + Keytruda (pembrolizumab) in patients with LA/ mUC who are unable to receive cisplatin-based CT treated in the 1L […]readmore
The PADCEV was evaluated in P-II EV-201 Trial to evaluate 125 patients locally advanced or metastatic urothelial cancer who received who received prior treatment with a PD-1 or PD-L1 inhibitor […]readmore
1. Sage Therapeutics Reports Results of SAGE-217 in P-III MOUNTAIN Study for Major Depressive Disorders Published: Dec 05, 2019 | Tags: Sage Therapeutics, Reports, Results, SAGE-217, P-III, MOUNTAIN Study, Major […]readmore
Shots: Seattle Genetics and Astellas sign a clinical trial agreement with Merck to evaluate the combination of Seattle Genetics’ and Astellas’ ADC and Merck’s anti-PD-1 therapy in patients with previously […]readmore
1. Triumvira’s TAC01-CD19 Receives FDA’s Fast Track Designation for R/R Diffuse Large B-Cell Lymphoma Published: Nov 07, 2019 | Tags: Triumvira, TAC01-CD19, Receives, FDA, Fast Track Designation, R/R, Diffuse Large B-Cell […]readmore
Shots: Seattle to receive upfront plus progress-dependent milestones of up to $160M and royalties on any product sales, retaining rights for candidates in Americas (the US, Canada, and Latin American […]readmore
Shots: The BLA submission is based on EV-201 P-II clinical study assessing Enfortumab Vedotin in patients with LA/m- urothelial cancer prior treated with PD-1/L1 inhibitor, including patients treated/not treated with […]readmore